ArticleBMC cancer2018
Low-dose aspirin use and survival in colorectal cancer: results from a population-based cohort study.
Article in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 37 citations in OpenAlex.
- Timing of Aspirin Use Among Patients With Colorectal Cancer in Relation to Mortality: A Systematic Review and Meta-Analysis.JNCI cancer spectrum · 2021Pooled it
- Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis.BMC cancer · 2020Pooled it
- Methodological Limitations in Aspirin-FIT Screening Research.Journal of gastroenterology and hepatology · 2026Article
- Chemoprevention of Colorectal Cancer-With Emphasis on Low-Dose Aspirin and Anticoagulants.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Potential Role of Benzoic Acid and its Synthetic Derivatives to Alleviate Cancer: An Up-to-Date Review.Current drug discovery technologies · 2025Review
- New Carbothioamide and Carboxamide Derivatives of 3-Phenoxybenzoic Acid as Potent VEGFR-2 Inhibitors: Synthesis, Molecular Docking, and Cytotoxicity Assessment.Current cancer drug targets · 2025Article
- Low-dose aspirin can inhibit exosomal release induced by radiotherapy in breast cancer and attenuate its inhibitory effect on NK cell proliferation.Cancer medicine · 2023Article
- Low-dose aspirin use and colorectal cancer survival in 32,195 patients-A national cohort study.Cancer medicine · 2023Article
- Colorectal cancer chemoprevention: is aspirin still in the game?Cancer biology & therapy · 2022Review
- Association of Prediagnosis Obesity and Postdiagnosis Aspirin With Survival From Stage IV Colorectal Cancer.JAMA network open · 2022Article
- Aspirin attenuates liver fibrosis by suppressing TGF‑β1/Smad signaling.Molecular medicine reports · 2022Article
- Article
- Associations of Aspirin and Non-Aspirin Non-Steroidal Anti-Inflammatory Drugs With Colorectal Cancer Mortality After Diagnosis.Journal of the National Cancer Institute · 2021Article
- Article
- Aspirin and cancer survival: a systematic review and meta-analyses of 118 observational studies of aspirin and 18 cancers.Ecancermedicalscience · 2021Review
- Aspirin as a Potential Geroprotector: Experimental Data and Clinical Evidence.Advances in experimental medicine and biology · 2021Article
- Prediagnostic use of low-dose aspirin and risk of incident metastasis and all-cause mortality among patients with colorectal cancer.British journal of clinical pharmacology · 2020Article
- Aspirin and the chemoprevention of cancers: A mathematical and evolutionary dynamics perspective.Wiley interdisciplinary reviews. Systems biology and medicine · 2020Review
- Improving prescribing through big data approaches-Ten years of the Scottish Prescribing Information System.British journal of clinical pharmacology · 2020Review
- Aspirin inhibits adipogenesis of tendon stem cells and lipids accumulation in rat injury tendon through regulating PTEN/PI3K/AKT signalling.Journal of cellular and molecular medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundAspirin has been proposed as a novel adjuvant agent in colorectal cancer (CRC). Six observational studies have reported CRC-specific survival outcomes in patients using aspirin after CRC diagnosis but the results from these studies have been conflicting. Using a population-based cohort design this study aimed to assess if low-dose aspirin use after diagnosis reduced CRC-specific mortality.
methodsA cohort of 8391 patients with Dukes' A-C CRC (2009-2012) was identified from the Scottish Cancer Registry and linked to national prescribing and death records. Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for CRC-specific mortality were calculated using time-dependent Cox regression.
resultsThere were 1064 CRC-specific deaths after a median follow-up of 3.6 years. Post-diagnostic low-dose aspirin use was not associated with a reduction in CRC-specific mortality either before or after adjustment for confounders (adjusted HR = 1.17, 95% CI 1.00-1.36). In sensitivity analysis pre-diagnostic low-dose aspirin was also not associated with reduced CRC-specific mortality (adjusted HR = 0.96, 95% CI 0.88-1.05).
conclusionLow-dose aspirin use, either before or after diagnosis, did not prolong survival in this population-based CRC cohort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.